PT-141 for Sale: Bremelanotide Research Overview and Sourcing Standards

Search for “PT-141 for sale” and you will find a market that reflects the compound’s unusual position: it is an FDA-approved drug, but it is also sold as a research chemical, and the two markets operate under entirely different rules. The clinical product is a prescription injection for a specific indication. The research product is a laboratory reference material. The names are the same; the regulatory frameworks are not.

This guide is written for laboratory researchers who need to evaluate a PT-141 supplier before placing an order. It covers what the published literature says about the compound, how the FDA-approved version differs from the research material, how to read a certificate of analysis without getting misled, and the specific questions that separate a transparent supplier from one that is hoping you will not ask.

What PT-141 is, and what the research shows

PT-141, also known as bremelanotide, is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors, particularly MC3R and MC4R. It is derived from melanotan II, a peptide that was originally studied for its effects on pigmentation. A 2014 review in Expert Opinion on Investigational Drugs describes melanocortin receptor agonists, including bremelanotide, as acting on central nervous system pathways rather than on the vascular system.

The clinical evidence base is substantial. The FDA approved bremelanotide in June 2019 under the brand name Vyleesi for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. The approval was based on two Phase 3 trials, RECONNECT, which evaluated the efficacy and safety of the drug in over 1,200 women. The trials showed that a higher proportion of women treated with bremelanotide reported increases in sexual desire and decreases in distress related to low sexual desire compared with placebo.

Later analyses have described the benefits in the Phase 3 trials as modest, and a 2021 re-analysis of the Phase III trials in the Journal of Sex Research questioned their clinical significance. According to the prescribing information, the most common adverse reactions were nausea, flushing, injection site reactions, and headache.

What the research does not establish is a safe and effective dose for any human use outside of the approved indication and the clinical trial context. The Vyleesi prescribing information states the recommended dose is 1.75 mg administered subcutaneously in the abdomen or thigh at least 45 minutes before anticipated sexual activity. The label also notes that the drug is not recommended for use more than once in 24 hours or more than eight times per month.

The difference between Vyleesi and research-grade PT-141

Researchers need to understand a distinction that is often blurred in online listings. Vyleesi is an FDA-approved prescription drug manufactured under a New Drug Application. The PT-141 sold by research peptide suppliers is a lyophilized powder labeled for laboratory research use only, not for diagnostic, therapeutic, or human use.

The Stack Research PT-141 product page states that the product is supplied only for lawful in-vitro laboratory or analytical research and that the page provides no dosing, administration, treatment, or diagnostic guidance. That boundary is the dividing line between a research supply business and a seller marketing an unapproved drug.

The distinction matters because the regulatory framework around an approved drug is entirely different from the framework around a research chemical. A supplier that sells research-grade PT-141 and markets it as equivalent to Vyleesi is misrepresenting the product. Bremelanotide is the active ingredient of an approved prescription drug, so selling it for human use outside the prescription system is distributing an unapproved drug, whatever the label says.

The researcher’s sourcing checklist for PT-141

The difference between a defensible purchase and a gamble comes down to documentation. Here is what to check, in order.

1. Lot-specific certificate of analysis, not a generic sample

A certificate of analysis (COA) is only meaningful if it corresponds to the exact lot you are buying. A supplier that shows a single COA for “PT-141” without tying it to a lot number is showing you marketing material, not a laboratory report. The COA should list the lot number, the testing laboratory, the report ID, the date the sample was received, and the date the results were published.

Stack Research publishes a lot-specific report for its PT-141 10 mg research peptide. The current lot documentation shows HPLC purity of 99.92 percent, measured content, and identity confirmation by mass spectrometry. The report identifies the testing laboratory and includes a report ID that can be cross-referenced. The product page shows the exact SKU, lot number, laboratory, report ID, and sample dates alongside the price.

2. What the COA actually tests

A certificate that lists only “purity: 99%” is incomplete. The useful fields are identity, purity by HPLC, measured content, endotoxin, and sterility. Identity confirms the peptide sequence matches the reference standard. Purity by HPLC shows the percentage of the sample that is the target compound. Measured content tells you how much peptide is actually in the vial, which can differ from the label. Endotoxin and sterility results speak to the handling conditions.

If a supplier’s COA omits measured content or endotoxin, that is a gap. It may not be a dealbreaker for every research context, but it is a data point about how thoroughly the supplier tests its material.

3. The research-use-only boundary

Every legitimate research peptide supplier uses the research-use-only (RUO) designation. The RUO label means the product is not intended for diagnostic, therapeutic, or human use. It is not a legal exemption: the FDA judges intended use from all of a seller’s marketing, and a product intended for human use is regulated as a drug regardless of the label.

What to watch for is a supplier that uses the RUO label while simultaneously publishing dosing information, before-and-after photos, or customer testimonials about human use. That combination is what the FDA has cited in warning letters. A supplier that maintains the boundary consistently is easier to trust because it is not trying to have it both ways.

4. Pricing and configuration transparency

PT-141 vials are typically sold in 10 mg configurations. The price per milligram should be calculable from the listing. If the listing obscures the vial size, bundles it with accessories, or requires a minimum order to see pricing, that is friction that makes comparison harder. Stack Research lists its 10 mg PT-141 vial at $54.90, with tiered volume pricing on multi-vial orders. The product page shows the exact SKU and lot information alongside the price, which makes the listing auditable.

How Stack Research approaches PT-141 documentation

Stack Research is a research peptide supplier that publishes lot-specific documentation for each product configuration. The company’s testing page describes the analytical methods used and the laboratories that perform the work. For researchers who need to verify a supplier before ordering, the relevant questions are whether the documentation is specific to the lot, whether the testing laboratory is named, and whether the results can be independently reviewed.

The PT-141 product page shows the current lot report directly on the page, with the purity, measured content, and identity results visible without requiring a separate download. The COA library collects the reports for all products so that researchers can compare documentation across configurations. The company maintains a research-use-only boundary throughout its product descriptions and does not publish dosing or administration guidance.

Comparing PT-141 documentation standards

The table below outlines the documentation elements that separate a transparent listing from an incomplete one. It is not a ranking of suppliers but a framework for evaluating any listing you encounter.

The table is not a guarantee. A supplier can produce all of these documents and still be selling a product that does not match the report, which is why independent testing services exist. But a supplier that cannot produce the documents at all is not worth the time it takes to evaluate further.

Common questions researchers ask before buying PT-141

Is PT-141 legal to buy for research purposes?

PT-141 is an FDA-approved prescription drug under the brand name Vyleesi, but the research peptide sold online is a different product category. A research-use label does not make the compound legal to sell or buy for human use. Outside a prescription for Vyleesi, bremelanotide is not approved for human use, and products marketed for personal use can be treated by the FDA as unapproved drugs.

What purity should a PT-141 COA show?

Purity by HPLC above 95 percent is the typical threshold for research-grade peptides. Many suppliers report 98 to 99 percent or higher. The purity figure is only meaningful alongside identity and content results. A vial can be 99 percent pure and still contain less peptide than the label claims if the fill is off.

How do I verify that a COA is real?

Check that the testing laboratory is named and that the report ID can be cross-referenced. Some laboratories publish verification portals where a report ID can be entered to confirm the document’s authenticity. If a supplier cannot tell you which laboratory performed the test, the COA cannot be independently verified.

What is the difference between PT-141 and bremelanotide?

They are the same compound. PT-141 is the research designation; bremelanotide is the international nonproprietary name; Vyleesi is the brand name. Researchers should confirm the identity of any product by its COA, not by the brand name on the vial.

What should I do if a supplier’s listing makes health claims?

Treat it as a disqualifying signal. Health claims on a research peptide listing are the exact pattern the FDA has cited in warning letters. A supplier that describes what the peptide “does” for the body is marketing an unapproved drug, regardless of the research-use label elsewhere on the page.

Can I compare PT-141 documentation across suppliers?

Yes, and you should. The relevant fields are comparable across suppliers: purity, identity, measured content, endotoxin, sterility, and lot traceability. The guide to reading a certificate of analysis walks through each field and explains what a complete report should contain.